GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » PB Ratio

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) PB Ratio

: 4.85 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Chugai Pharmaceutical Co's share price is $33.27. Chugai Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2023 was $6.86. Hence, Chugai Pharmaceutical Co's PB Ratio of today is 4.85.

The historical rank and industry rank for Chugai Pharmaceutical Co's PB Ratio or its related term are showing as below:

CHGCF' s PB Ratio Range Over the Past 10 Years
Min: 1.93   Med: 4.44   Max: 11.2
Current: 5.3

During the past 13 years, Chugai Pharmaceutical Co's highest PB Ratio was 11.20. The lowest was 1.93. And the median was 4.44.

CHGCF's PB Ratio is ranked worse than
85.45% of 962 companies
in the Drug Manufacturers industry
Industry Median: 1.91 vs CHGCF: 5.30

During the past 12 months, Chugai Pharmaceutical Co's average Book Value Per Share Growth Rate was 14.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 18.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Chugai Pharmaceutical Co was 18.60% per year. The lowest was 2.30% per year. And the median was 6.60% per year.

Back to Basics: PB Ratio


Chugai Pharmaceutical Co PB Ratio Historical Data

The historical data trend for Chugai Pharmaceutical Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.48 8.05 5.09 3.99 5.39

Chugai Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.99 3.81 4.56 4.83 5.39

Competitive Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's PB Ratio falls into.



Chugai Pharmaceutical Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chugai Pharmaceutical Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=33.27/6.862
=4.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Chugai Pharmaceutical Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines